TY - JOUR
T1 - GARFIELD-AF
T2 - a worldwide prospective registry of patients with atrial fibrillation at risk of stroke
AU - Bassand, Jean-Pierre
AU - Apenteng, Patricia N
AU - Atar, Dan
AU - Camm, A John
AU - Cools, Frank
AU - Corbalan, Ramon
AU - Fitzmaurice, David A
AU - Fox, Keith Aa
AU - Goto, Shinya
AU - Haas, Sylvia
AU - Hacke, Werner
AU - Jerjes-Sanchez, Carlos
AU - Koretsune, Yukihiro
AU - Heuzey, Jean-Yves Le
AU - Sawhney, Jitendra Ps
AU - Oh, Seil
AU - Stępińska, Janina
AU - Cate, Vincent Ten
AU - Verheugt, Freek Wa
AU - Kayani, Gloria
AU - Pieper, Karen S
AU - Kakkar, Ajay K
AU - GARFIELD-AF Investigators
PY - 2021/1
Y1 - 2021/1
N2 - The Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) examined real-world practice in a total of 57,149 (5069 retrospective, 52,080 prospective) patients with newly diagnosed AF at risk of stroke/systemic embolism, enrolled at over 1000 centers in 35 countries. It aimed to capture data on AF burden, patients' clinical profile, patterns of clinical practice and antithrombotic management, focusing on stroke/systemic embolism prevention, uptake of new oral anticoagulants, impact on death and bleeding. GARFIELD-AF set new standards for quality of data collection and analysis. A total of 36 peer-reviewed articles were already published and 73 abstracts presented at international congresses, covering treatment strategies, geographical variations in baseline risk and therapies, adverse outcomes and common comorbidities such as heart failure. A risk prediction tool as well as innovative observational studies and artificial intelligence methodologies are currently being developed by GARFIELD-AF researchers. Clinical Trial Registration: NCT01090362 (ClinicalTrials.gov).
AB - The Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) examined real-world practice in a total of 57,149 (5069 retrospective, 52,080 prospective) patients with newly diagnosed AF at risk of stroke/systemic embolism, enrolled at over 1000 centers in 35 countries. It aimed to capture data on AF burden, patients' clinical profile, patterns of clinical practice and antithrombotic management, focusing on stroke/systemic embolism prevention, uptake of new oral anticoagulants, impact on death and bleeding. GARFIELD-AF set new standards for quality of data collection and analysis. A total of 36 peer-reviewed articles were already published and 73 abstracts presented at international congresses, covering treatment strategies, geographical variations in baseline risk and therapies, adverse outcomes and common comorbidities such as heart failure. A risk prediction tool as well as innovative observational studies and artificial intelligence methodologies are currently being developed by GARFIELD-AF researchers. Clinical Trial Registration: NCT01090362 (ClinicalTrials.gov).
KW - Anticoagulants/therapeutic use
KW - Artificial Intelligence
KW - Atrial Fibrillation/complications
KW - Humans
KW - Prospective Studies
KW - Registries
KW - Retrospective Studies
KW - Risk Factors
KW - Stroke/epidemiology
U2 - 10.2217/fca-2020-0014
DO - 10.2217/fca-2020-0014
M3 - Article
C2 - 32696663
SN - 1479-6678
VL - 17
SP - 19
EP - 38
JO - Future Cardiology
JF - Future Cardiology
IS - 1
ER -